Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Evecxia is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Kaiser played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Evecxia
Evecxia is a privately funded, clinical stage pharmaceutical company, located in the Research Triangle Park, NC. Evecxias mission is to develop and commercialize EVX-101 and related drug candidates to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal. Evecxia is the first company dedicated to realizing the therapeutic potential of 5-HTP via specialized Rx combinations and drug delivery dosage forms. Evecxia has licensed a comprehensive portfolio of issued and pending patents on the 5-HTP slow-release method and related technologies from Duke University and Duke-National University Singapore.

To learn more about Evecxia, visit http://evecxia.com/

Contact:
John Kaiser, Chief Executive Officer
919-597-8762
https://www.linkedin.com/in/jkaiserbiopharmexec/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved